阿斯利康同意以最多 24 亿美元收购生物技术集团 Fusion。 AstraZeneca agrees to acquire biotech group Fusion for up to $2.4bn.

制药巨头阿斯利康 (AstraZeneca) 已同意以最多 24 亿美元收购肿瘤药物开发商 Fusion Pharmaceuticals，旨在扩大其癌症治疗产品组合。 Pharma giant AstraZeneca has agreed to acquire oncology drugs developer Fusion Pharmaceuticals for up to $2.4 billion, aiming to expand its cancer treatment portfolio. 该交易预计将于 2022 年底完成，需满足惯例成交条件和监管部门的批准。 The deal, expected to close by the end of 2022, is subject to customary closing conditions and regulatory approvals. Fusion Pharma 专注于靶向 α 疗法，该疗法使用放射性同位素来治疗各种癌症。 Fusion Pharma specializes in targeted alpha therapy, which uses radioactive isotopes to treat various cancers.